Drug Profile
RLYB 331
Alternative Names: KY-1066; RLYB-331Latest Information Update: 11 Aug 2022
Price :
$50
*
At a glance
- Originator Kymab
- Class Antianaemics; Monoclonal antibodies
- Mechanism of Action Matriptase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Iron overload
- Research Anaemia
Most Recent Events
- 11 Aug 2022 RLYB 331 is still in preclinical trials for Anaemia (associated with Iron Overload Disorders) in the United Kingdom (Parenteral)
- 10 May 2022 Rallybio in-licenses RLYB 331 from Sanofi
- 28 Feb 2022 No recent reports of development identified for research development in Anaemia in United Kingdom